Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2020

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

1 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
2 Unibas - Université de Bâle = University of Basel = Basel Universität
3 Vilnius University [Vilnius]
4 Royal Infirmary of Edinburgh
5 WUSTL - Washington University in Saint Louis
6 Duke University [Durham]
7 GU - Georgetown University [Washington]
8 Royal Marsden Hospital [Surrey, UK]
9 Vanderbilt University Medical Center [Nashville]
10 UNIBE - Universität Bern / University of Bern
11 University of Pennsylvania
12 Faculty of Medicine in Hradec Kralove [Republique Tchèque]
13 ESMO - European Institute of Oncology [Milan]
14 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
15 Hôpital Lariboisière-Fernand-Widal [APHP]
16 University of Naples Federico II = Università degli studi di Napoli Federico II
17 UCY - University of Cyprus [Nicosia]
18 “Attikon” University Hospital
19 University of Athens Medical School [Athens]
20 Medizinische Universität Wien = Medical University of Vienna
21 DZHK - German Center for Cardiovascular Research
22 UMG - University Medical Center Göttingen
23 Sechenov First Moscow State Medical University
24 TAU - Tel Aviv University
25 University Hospital of Würzburg
26 University of the Study of Campania Luigi Vanvitelli
27 University hospital of Zurich [Zurich]
28 University of Warwick [Coventry]
29 IRCCS San Raffaele [Rome, Italy]
30 University of Belgrade [Belgrade]
31 University of Ljubljana
32 Piacenza Hospital
33 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
34 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
35 LUMC - Leiden University Medical Center
36 CIC 1418 - CIC - HEGP
37 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
38 AUB - American University of Beirut Faculty of Medicine and Medical Center
39 Inselspital - Bern University Hospital [Berne]
40 La Paz University Hospital
41 UMCG - University Medical Center Groningen [Groningen]
42 Imperial College London
Riccardo Asteggiano
  • Fonction : Auteur

Résumé

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.

Dates et versions

hal-03676846 , version 1 (24-05-2022)

Identifiants

Citer

Radek Pudil, Christian Mueller, Jelena Čelutkienė, Peter Henriksen, Dan Lenihan, et al.. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22 (11), pp.1966-1983. ⟨10.1002/ejhf.2017⟩. ⟨hal-03676846⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More